ArticleNature communications2024
Longitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic performance of 18F-FDG PET/CT metabolic parameters for early prediction of pathological response in NSCLC treated with neoadjuvant immuno(chemo)therapy: A systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2026Pooled it
- Immune-metabolic profiling of triple-negative breast cancer during neoadjuvant chemotherapy.iScience · 2026Article
- Single-cell analysis reveals an endothelial TP53-CXCL14 axis in breast cancer progression.Journal of translational medicine · 2026Article
- Glucose metabolic reprogramming as a driver of immunosuppression in the tumour microenvironment.Clinical and translational medicine · 2026Review
- TMEM70 drives breast cancer progression via mitochondrial oxidative phosphorylation and microenvironment remodeling.Cancer cell international · 2026Article
- Longitudinal deep learning models for tracking disease progression in ovarian cancer using PET/CT imaging and clinical reports.Physical and engineering sciences in medicine · 2026Article
- Longitudinal MRI-based deep learning model for predicting pathological complete response in breast cancer: a multicenter, retrospective cohort study.NPJ precision oncology · 2026Article
- Tertiary lymphoid structures are associated with lower axillary residual nodal burden in breast cancer patients after neoadjuvant chemotherapy.European journal of medical research · 2025Article
- Nanostrategies synergize with locoregional interventional therapies for boosting antitumor immunity.Bioactive materials · 2025Article
- Article
- Targeting Resistance Pathways in Breast Cancer Through Precision Oncology: Nanotechnology and Immune Modulation Approaches.Biomedicines · 2025Review
- Apoptotic priming in senescence predicts specific senolysis by quantitative analysis of mitochondrial dependencies.Cell death and differentiation · 2025Article
- Lipid metabolic reprograming: the unsung hero in breast cancer progression and tumor microenvironment.Molecular cancer · 2025Review
- Bioinformatics Identification of Lactate-Associated Genes in Hepatocellular Carcinoma: G6PD's Role in Immune Modulation.Cancer medicine · 2025Article
- Immune monitoring of neoadjuvant chemo-immunotherapy for triple-negative breast cancer.Frontiers in immunology · 2025Review
- The interplay between the immune response and neoadjuvant therapy in breast cancer.Frontiers in oncology · 2025Review
- Another power of antibody-drug conjugates: immunomodulatory effect and clinical applications.Frontiers in immunology · 2025Review
- Machine learning in oncological pharmacogenomics: advancing personalized chemotherapy.Functional & integrative genomics · 2024Review
- Longitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer.Nature communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although metabolic reprogramming within tumor cells and tumor microenvironment (TME) is well described in breast cancer, little is known about how the interplay of immune state and cancer metabolism evolves during treatment. Here, we characterize the immunometabolic profiles of tumor tissue samples longitudinally collected from individuals with breast cancer before, during and after neoadjuvant chemotherapy (NAC) using proteomics, genomics and histopathology. We show that the pre-, on-treatment and dynamic changes of the immune state, tumor metabolic proteins and tumor cell gene expression profiling-based metabolic phenotype are associated with treatment response. Single-cell/nucleus RNA sequencing revealed distinct tumor and immune cell states in metabolism between cold and hot tumors. Potential drivers of NAC based on above analyses were validated in vitro. In summary, the study shows that the interaction of tumor-intrinsic metabolic states and TME is associated with treatment outcome, supporting the concept of targeting tumor metabolism for immunoregulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.